Matthew A Spinelli1, Beatriz Grinsztejn2, Raphael J Landovitz3. 1. Division of HIV, ID, and Global Medicine, University of California, San Francisco, California, USA. 2. Instituto de Pesquisa Clinica Evandro Cha-gas-Fiocruz, Rio De Janeiro, Brasil. 3. UCLA Center for Clinical AIDS Research and Education, Los Angeles, California, USA.
Abstract
PURPOSE OF REVIEW: Tenofovir-based oral PrEP has been effective in reducing population-level HIV incidence in multiple settings, although disparities remain. Injectable cabotegravir-based PrEP is an alternative that may be attractive to individuals with adherence challenges or who do not desire to take a daily medication. We review promises and challenges of cabotegravir-based PrEP. RECENT FINDINGS: Cabotegravir has demonstrated higher effectiveness than oral PrEP in two randomized trials, with a hazard ratio of 0.31 for HIV incidence among MSM and transgender women across multiple settings [95% confidence interval (CI) 0.18-0.62] and 0.11 for cisgender women in sub-Saharan Africa (95% CI 0.040.32). Cabotegravir was also highly effective among populations with disproportionate HIV incidence. Although cabotegravir breakthrough was rare, diagnosis was delayed with use of antigen/antibody-based HIV tests, and resistance occurred with breakthrough infections. Implementation will need to overcome several challenges, including HIV RNA laboratory monitoring not being widely available, requirement for additional staff time and clinic space, and need to provide oral medication during interruptions in dosing. SUMMARY: Cabotegravir-based PrEP is a highly effective additional PrEP option that will expand HIV prevention options. For successful roll-out, strategies for streamlined and accessible delivery of cabotegravir in real-world settings will need to be developed.
PURPOSE OF REVIEW: Tenofovir-based oral PrEP has been effective in reducing population-level HIV incidence in multiple settings, although disparities remain. Injectable cabotegravir-based PrEP is an alternative that may be attractive to individuals with adherence challenges or who do not desire to take a daily medication. We review promises and challenges of cabotegravir-based PrEP. RECENT FINDINGS: Cabotegravir has demonstrated higher effectiveness than oral PrEP in two randomized trials, with a hazard ratio of 0.31 for HIV incidence among MSM and transgender women across multiple settings [95% confidence interval (CI) 0.18-0.62] and 0.11 for cisgender women in sub-Saharan Africa (95% CI 0.040.32). Cabotegravir was also highly effective among populations with disproportionate HIV incidence. Although cabotegravir breakthrough was rare, diagnosis was delayed with use of antigen/antibody-based HIV tests, and resistance occurred with breakthrough infections. Implementation will need to overcome several challenges, including HIV RNA laboratory monitoring not being widely available, requirement for additional staff time and clinic space, and need to provide oral medication during interruptions in dosing. SUMMARY: Cabotegravir-based PrEP is a highly effective additional PrEP option that will expand HIV prevention options. For successful roll-out, strategies for streamlined and accessible delivery of cabotegravir in real-world settings will need to be developed.
Authors: Catherine A Koss; Peter Bacchetti; Sharon L Hillier; Edward Livant; Howard Horng; Nyaradzo Mgodi; Brenda G Mirembe; Kailazarid Gomez Feliciano; Stephanie Horn; Albert Y Liu; David V Glidden; Robert M Grant; Leslie Z Benet; Alexander Louie; Ariane van der Straten; Z Mike Chirenje; Jeanne M Marrazzo; Monica Gandhi Journal: AIDS Res Hum Retroviruses Date: 2017-03-02 Impact factor: 2.205
Authors: Jeanne M Marrazzo; Gita Ramjee; Barbra A Richardson; Kailazarid Gomez; Nyaradzo Mgodi; Gonasagrie Nair; Thesla Palanee; Clemensia Nakabiito; Ariane van der Straten; Lisa Noguchi; Craig W Hendrix; James Y Dai; Shayhana Ganesh; Baningi Mkhize; Marthinette Taljaard; Urvi M Parikh; Jeanna Piper; Benoît Mâsse; Cynthia Grossman; James Rooney; Jill L Schwartz; Heather Watts; Mark A Marzinke; Sharon L Hillier; Ian M McGowan; Z Mike Chirenje Journal: N Engl J Med Date: 2015-02-05 Impact factor: 91.245
Authors: Chloe Orkin; Enrique Bernal Morell; Darrell H S Tan; Harold Katner; Hans-Jürgen Stellbrink; Elena Belonosova; Rebecca DeMoor; Sandy Griffith; Shanker Thiagarajah; Rodica Van Solingen-Ristea; Susan L Ford; Herta Crauwels; Parul Patel; Amy Cutrell; Kimberly Y Smith; Kati Vandermeulen; Eileen Birmingham; Marty St Clair; William R Spreen; Ronald D'Amico Journal: Lancet HIV Date: 2021-10-14 Impact factor: 12.767
Authors: Kimberly Elizabeth Green; Long Hoang Nguyen; Huong Thu Thi Phan; Bao Ngoc Vu; Minh Hung Tran; Huu Van Ngo; Van Thi Thu Tieu; Hung Van; Thanh Minh Le; Khang Quang Do; Phong Anh Nguyen; Trang Minh Ngo; Anh Hong Doan; Diep Thi Ngoc Bui; Trang Nguyen Nhu Nguyen; Lan Thi Xuan Hang; Tham Thi Tran; Binh Quoc Luong Journal: Sex Health Date: 2021-03 Impact factor: 2.706
Authors: Douglas Krakower; Kevin M Maloney; Victoria E Powell; Ken Levine; Chris Grasso; Kathy Melbourne; Julia L Marcus; Kenneth H Mayer Journal: J Int AIDS Soc Date: 2019-02 Impact factor: 5.396
Authors: Alexandra M Minnis; Millicent Atujuna; Erica N Browne; Sheily Ndwayana; Miriam Hartmann; Siyaxolisa Sindelo; Nangamso Ngcwayi; Marco Boeri; Carol Mansfield; Linda-Gail Bekker; Elizabeth T Montgomery Journal: J Int AIDS Soc Date: 2020-06 Impact factor: 5.396